Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Colorectal Cancer
Interventions
DRUG

Capecitabine

DRUG

Irinotecan

Trial Locations (17)

10451

Lincoln Medical and Mental Health Center, The Bronx

11235

HemOnCare, P.C., Brooklyn

19111

Fox Chase Cancer Center, Philadelphia

20007

Lombardi Cancer Center at Georgetown University Medical Center, Washington D.C.

20037

George Washington University Medical Center, Washington D.C.

22908

Cancer Center at the University of Virginia, Charlottesville

29403

Charleston Hematology-Oncology, P.A., Charleston

32209

University of Florida Health Science Center - Jacksonville, Jacksonville

92354

Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda

98104

Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle

99202

Rockwood Clinic P.S., Spokane

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

06360

Eastern Connecticut Hematology and Oncology Associates, Norwich

40536-0084

Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington

63110-0250

St. Louis University Hospital Cancer Center, St Louis

19107-5541

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia

26506-9300

West Virginia University Hospitals, Morgantown

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00022698 - Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter